Entropy Neurodynamics CEO to Showcase Clinical Advances and TRP-8803 Platform at TechKnow Invest Roadshow

TRP-8803: Entropy Neurodynamics’ Innovative IV-Infused Psilocin Platform

Entropy Neurodynamics’ lead candidate, TRP-8803, is a proprietary intravenously infused psilocin formulation—the active metabolite of psilocybin—designed to overcome key limitations of oral psilocybin administration. The company has identified several advantages of its IV approach, including a significantly faster onset of the psychedelic effect, enhanced control over the intensity and duration of the experience, and a reduced overall treatment timeframe that is commercially viable. This differentiated platform addresses practical challenges in clinical delivery and patient experience that have hindered other psychedelic-assisted therapies.

TRP-8803 development builds on insights from prior Phase 2a oral psilocybin trials conducted across three indications: Binge Eating Disorder, Irritable Bowel Syndrome, and Fibromyalgia. These studies demonstrated clinical benefits of psychedelic-assisted therapy, supporting the company’s strategic focus on TRP-8803. Learnings from these oral programs are being leveraged to optimize both the drug formulation and therapeutic protocols for the IV-infused platform.

Positive Phase 2 Topline Results in Treatment-Resistant Binge Eating Disorder Trial

Entropy Neurodynamics recently disclosed encouraging Phase 2 topline results from Cohort 1 of its treatment-resistant Binge Eating Disorder trial, which will be a central topic in CEO Jason Carroll’s roadshow presentation. Binge Eating Disorder presents a significant unmet medical need, especially for patients unresponsive to existing treatments. These positive Phase 2 outcomes mark a major milestone in the company’s clinical development and validate the therapeutic approach of TRP-8803. Detailed efficacy, safety data, and patient demographics are included in the presentation materials accompanying the company update.

The broader strategic impact of the BED trial extends beyond this single indication. Success in treatment-resistant BED may inform development strategies for other neuropsychiatric disorders with similar therapeutic mechanisms. The roadshow will explore how these results position TRP-8803 competitively within the neuropsychiatric treatment landscape, offering investors critical insights into the company’s pipeline potential and commercial addressable market.

Expansive Commercial Potential Across Neuropsychiatric Disorders

Entropy Neurodynamics pursues a multi-indication development strategy, with TRP-8803 being evaluated or planned for evaluation in several neuropsychiatric conditions. The roadshow presentation will highlight the "significant commercial opportunity across multiple neuropsychiatric indications," reflecting management’s confidence in the platform’s broad applicability. Prior Phase 2a trials with oral psilocybin in Binge Eating Disorder, Irritable Bowel Syndrome, and Fibromyalgia demonstrate the therapeutic promise of psychedelic-assisted therapy across diverse conditions with high unmet needs.

Commercial success depends on demonstrating clinical efficacy, securing regulatory approvals, and establishing reimbursement pathways across multiple indications. Neuropsychiatric disorders represent a vast global market, including depression, anxiety, and eating disorders affecting millions. TRP-8803’s potential as a platform technology could drive substantial value creation if clinical development proceeds successfully. The company’s focus on unmet needs positions it to target patient populations underserved by current treatments, potentially facilitating regulatory approval and market adoption.

Roadshow Engagements in Melbourne and Sydney: Direct Investor Access

Entropy Neurodynamics’ participation in the TechKnow Invest Roadshow in Melbourne (27 July 2026) and Sydney (29 July 2026) provides direct engagement opportunities with institutional and retail investors. CEO Jason Carroll will personally present, offering insights into the company’s clinical progress, strategic direction, and pipeline development. These presentations typically include Q&A sessions, enabling deeper discussions on clinical, regulatory, and commercial strategies beyond written disclosures. Hosting events in Australia’s two largest financial hubs underscores a focus on engaging domestic institutional investors and fund managers.

For investors considering Entropy Neurodynamics, these roadshows offer a chance to evaluate management expertise, gain detailed understanding of the clinical strategy, and assess views on competitive positioning and market timing. Presentation materials accompanying the update will be available, providing a comprehensive record of disclosed information. Attendees and remote investors alike can assess clinical progress, intellectual property strength around TRP-8803, and management’s confidence in the development and commercial outlook.

Clinical-Stage Biotech with Focus on Unmet Medical Needs

As a clinical-stage biotech company, Entropy Neurodynamics has advanced beyond early development but has not yet obtained regulatory approval or commercialized its lead asset. This stage presents both opportunities and risks for investors. Successful clinical development and regulatory clearance of TRP-8803 could generate significant shareholder value by establishing market presence across neuropsychiatric indications. The company’s targeted focus on diseases with unmet needs aims to capitalize on therapeutic areas lacking effective treatments, potentially easing regulatory and market entry challenges.

However, value realization depends on successful trial completion, positive regulatory outcomes, and commercialization. Investors face risks including trial failures, regulatory setbacks, or limited market uptake. The company’s prior Phase 2a oral psilocybin trials provide some clinical feasibility evidence, but TRP-8803’s success and valuation will hinge on ongoing and future trial results.

Regulatory and Safety Aspects of Psilocin-Based Treatments

The company update outlines risks linked to psilocin and related psychedelics, reflecting regulatory and safety considerations for this therapeutic class. It emphasizes that all medicines carry risks and that specialist prescribers, especially registered psychiatrists, are best suited to evaluate patient suitability. Potential adverse effects include temporary blood pressure increases and elevated heart rate, with some risk of psychosis in genetically predisposed individuals. These factors are critical to regulatory review and clinical use of TRP-8803.

Nonetheless, adverse effects are unlikely at low doses within controlled psychedelic-assisted psychotherapy settings under medical supervision. The IV-infused TRP-8803 formulation offers enhanced dose and duration control compared to oral forms, potentially improving safety via precise pharmacokinetics. Regulators will assess safety data alongside these considerations to determine the therapy’s risk-benefit profile.

Investor Relations and Shareholder Communication Enhancements

Entropy Neurodynamics encourages investors to register with the Automic Group investor portal for updates and communication management. This platform supports efficient shareholder engagement and timely dissemination of material information. Shareholders can opt for electronic communications by registering with their Holding Number and registered address, aligning with modern corporate governance best practices and reducing communication costs.

Presentation materials from the roadshow will be accessible via company updates and investor relations channels, ensuring shareholders unable to attend can access the same disclosures. This transparency aids informed decision-making. Investors yet to register with Automic are urged to do so to stay informed on critical clinical milestones and regulatory developments impacting ENP stock performance.

Forward-Looking Statements and Milestone Monitoring

The update contains forward-looking statements about expectations, projections, and future events, including terms like "plans," "targets," "expects," "is positioned," "intends," and "anticipates." The company cautions that actual outcomes may differ materially due to risks and uncertainties detailed in its Replacement Prospectus on the ASX website.

Investors should track upcoming development milestones discussed during the roadshow, such as clinical trial progress, regulatory interactions, and timelines for advancing TRP-8803 toward later-stage studies or submissions. The company disclaims any obligation to update forward-looking statements except as legally required. Monitoring announced milestones against actual progress is essential for evaluating execution and clinical program success probabilities.

Neuropsychiatric Market Potential and Competitive Edge

The global neuropsychiatric therapeutics market offers a substantial opportunity, covering depression, anxiety, Binge Eating Disorder, PTSD, and treatment-resistant psychiatric illnesses. Many lack effective treatments, especially in resistant populations. Entropy Neurodynamics’ focus on unmet needs positions TRP-8803 in a favorable regulatory and market environment, supported by recent global regulatory openness to psychedelic-assisted therapies.

Its IV-infused psilocin platform may offer competitive advantages over oral psilocybin and other psychedelic formulations by enabling control over onset, intensity, duration, and treatment timeframe. This distinct value proposition could improve treatment feasibility, patient experience, and outcomes. However, the psychedelic therapeutics space is competitive, with multiple companies pursuing similar programs. Success will depend on clinical differentiation, intellectual property protection, and capturing market share across neuropsychiatric indications.